1. Introduction {#sec1-ijms-20-00317}
===============

Natural killer (NK) cells are innate immune cells that were first discovered in mice in 1975 \[[@B1-ijms-20-00317]\]. NK cells account for approximately 10% of lymphocytes in human peripheral blood (PB). Owing to the distinct chemokine receptors expressed in NK cells, the distributions of NK cells differ among healthy tissues. Most NK cells are found in the PB, liver, spleen, and bone marrow, and a small portion are also present in the lymph nodes \[[@B2-ijms-20-00317],[@B3-ijms-20-00317],[@B4-ijms-20-00317],[@B5-ijms-20-00317]\]. NK cells are part of the first line of defense that protects the body from pathogen invasion and malignant transformation. When normal cells are infected by viruses, NK cells are rapidly activated to protect against abnormal and virus-infected cells, without prior sensitization \[[@B5-ijms-20-00317],[@B6-ijms-20-00317],[@B7-ijms-20-00317]\].

In recent studies, as our understanding of tumor immunology has deepened, the basic research and clinical applications of NK cells has become an interesting topic. Some studies have shown that allogeneic NK cells have stronger tumor killing ability than autologous NK cells \[[@B8-ijms-20-00317]\]. Moreover, allogeneic NK cells can be obtained from many sources, such as bone marrow, human embryonic stem cells, induced pluripotent stem cells, PB, and umbilical cord blood. However, these NK cells are difficult to purify and expand in vitro. With the gradual advancement of cell cloning technology, many NK cell lines have been established, including KHYG-1, NK-92, NKL, NKG, and YT cells. All of these cell lines are characterized by a uniform phenotype, high purity, and function, consistent with the general characteristics of NK cells. These cells can also be cultured at a large scale in vitro, thus providing sufficient cells for research and clinical applications. Among these cell lines, NK-92 cells are the most widely used line that have been approved for clinical use. Additionally, chimeric antigen receptor (CAR)-modified NK-92 (CAR-NK-92) cells have shown strong antitumor effects.

In this review, we summarize the established human NK cell lines and their biological characteristics and highlight the applications of NK-92 cells and CAR-NK-92 cells in tumor immunotherapy.

2. Receptor Distribution and Killing Mechanism of NK Cells {#sec2-ijms-20-00317}
==========================================================

As the body's first line of defense, many surface molecules ([Figure 1](#ijms-20-00317-f001){ref-type="fig"}) are expressed on NK cells \[[@B9-ijms-20-00317],[@B10-ijms-20-00317]\], which are characterized by the expression of CD56 and CD16 cell surface markers, and absence of T-cell receptor (TCR) and B-cell receptor. According to differences in CD56 and CD16 expression density, two major subsets of NK cells can be distinguished, i.e., CD56bright and CD56dim \[[@B3-ijms-20-00317],[@B5-ijms-20-00317],[@B11-ijms-20-00317],[@B12-ijms-20-00317]\]. CD56dim NK cells are fully mature, account for approximately 90% of the NK cells in the PB, and predominantly mediate cytotoxicity responses \[[@B5-ijms-20-00317]\]. CD56dim cells can play roles in antibody-dependent cell-mediated cytotoxicity (ADCC) through the surface expression of CD16 (FcγRIII) \[[@B13-ijms-20-00317],[@B14-ijms-20-00317],[@B15-ijms-20-00317]\]. CD56bright cells are immature, account for approximately 5--15% of the NK cells in the PB, and are predominant in tissues and secondary lymphoid organs \[[@B16-ijms-20-00317]\]. CD56bright cells express high levels of CD56, CD94/NKG2A,[l]{.smallcaps}-selectin, and a high-affinity interleukin (IL)-2 receptor, but little to no CD16 and killer-cell immunoglobulin-like receptor. Therefore, CD56bright cells function primarily to secrete cytokines, such as interferon-γ, tumor necrosis factor (TNF)-α, and granulocyte macrophage-colony-stimulating factor \[[@B11-ijms-20-00317],[@B17-ijms-20-00317]\].

NK cells do not express antigen-specific recognition receptors. There are two receptors with opposite functions on their surface. The first type of receptor can bind to its corresponding ligand on the surface of the target cell, activating the killing effects of NK cells. This receptor is called the activating NK cell receptor \[[@B18-ijms-20-00317]\]. The other type of receptor, called the inhibitory NK cell receptor, inhibits the killing effect of NK cells \[[@B18-ijms-20-00317]\].

Both the activating receptor and inhibitory receptor can recognize classical or nonclassical major histocompatibility complex (MHC) class I molecules expressed on the surface of normal cells. Inhibitory receptors play a primary role in preventing NK cells from killing normal cells \[[@B19-ijms-20-00317],[@B20-ijms-20-00317]\]. In virus-infected cells and tumor cells, MHC class I molecules on the cell surface are lost or downregulated; activating NK cell receptors play a leading role in this process.

Activated NK cells exert cytotoxic effects mainly through three pathways ([Figure 2](#ijms-20-00317-f002){ref-type="fig"}). The first pathway is the perforin/granzyme pathway \[[@B9-ijms-20-00317]\]. In this pathway, granzymes and perforin stored in the cytoplasmic granules of NK cells are released by activated NK cells together into the intercellular space. The structure of perforin is similar to that of complement, which can form a transmembrane channel directly on the target cell membrane, resulting in increased permeability of the cell membrane and ultimately causing osmotic lysis of the target cell. The perforation channel formed by perforin facilitates the entry of granzyme into the target cell. Additionally, perforin causes redistribution of granzymes in the cytoplasm and nucleus of target cells, allowing granzymes to accumulate at the cleavage site; this promotes the lysis of target cells and ultimately apoptosis. The second pathway is the Fas/FasL pathway \[[@B21-ijms-20-00317],[@B22-ijms-20-00317]\]. The Fas molecule, also known as Apo-1 or CD95, is a type-Ⅰ transmembrane protein, and Fas ligand (FasL or CD95L) is a type-Ⅱ transmembrane protein that belongs to the TNF family. When FasL binds to Fas, Fas can deliver a "death signal" to the cell, and the target cell then undergoes apoptosis within a few hours. In the third pathway, the cytokine pathway, NK cells secrete cytokines, e.g., TNF-α \[[@B9-ijms-20-00317]\], which can alter the stability of lysosomes in target cells, leading to leakage of various hydrolases, affecting cell membrane phospholipid metabolism, and activating target cell endonuclease to degrade genomic DNA.

3. Currently Known NK Cell Lines {#sec3-ijms-20-00317}
================================

NK cell lines are monoclonal cells that can survive permanently in vitro. Here, we summarize currently established primary NK cell lines ([Table 1](#ijms-20-00317-t001){ref-type="table"}).

3.1. NK3.3 Cells {#sec3dot1-ijms-20-00317}
----------------

NK3.3 cells are a normal NK-derived cell line obtained by Kornbluth and co-workers in 1982 \[[@B23-ijms-20-00317]\]. These cells are dependent on Interleukin-2 (IL-2) and are positive for CD2, CD11a, CD38, CD45, CD16, and CD56 \[[@B24-ijms-20-00317]\]. The morphology, immunohistochemistry, and phenotype of NK3.3 cells are similar to those of large granular lymphocytes (LGLs). NK3.3 cells have very strong cytotoxicity, which can kill NK-sensitive target cells, such as K562 and MOLT-4 cells \[[@B23-ijms-20-00317],[@B25-ijms-20-00317],[@B26-ijms-20-00317]\].

3.2. YT Cells {#sec3dot2-ijms-20-00317}
-------------

The YT cell line was established in 1983 by Yodoi and co-workers, derived from a 15-year-old pericardial effusion of a Japanese man suffering from acute lymphoma and thymoma \[[@B27-ijms-20-00317]\]. YT cells show varying sizes, irregular nuclei, and abundant vacuoles, and azurophilic particles in the cytoplasm. Additionally, YT cells are positive for CD56 and negative for CD2, CD3, and CD16. Importantly, YT cells can undergo long-term in vitro expansion without the need for conditioned medium or IL-2. Moreover, YT cells have toxic effects on cancer cells, such as K562, MOLT-4, HPB-ALL, and HSB-2 cells.

YT2C2 and YTC3 cells are two subclones of YT cells \[[@B28-ijms-20-00317]\]. These two cell subclones do not mediate ADCC. However, these cell lines can kill 721.221 cells with high expression of B7.1 \[[@B29-ijms-20-00317]\]. Cytotoxicity analysis showed that YT2C2 and YTC3 cells primarily rely on cell surface receptor-mediated cytotoxicity.

3.3. NKL Cells {#sec3dot3-ijms-20-00317}
--------------

The NKL cell line was established in 1996 by Robertson and co-workers and was derived from the PB of a patient with LGL leukemia \[[@B30-ijms-20-00317]\]. NKL cells require IL-2 for sustained growth and die if deprived of IL-2 for more than 7 days. The morphology of NKL cells is similar to that of activated NK cells, which have natural killing activity and can mediate ADCC. According to phenotypic analysis, NKL cells overexpress CD2, CD6, CD11a, CD27, CD29, CD38, CD43, CD58, CD94, and CD95, but are negative for CD3, CD4, CD5, CD8, CD14, CD19, CD20, and CD28. As the culture time in vitro increased, the cell surface expression of CD16, CD56, and CD57 and the antigen density were significantly reduced.

3.4. HANK1 Cells {#sec3dot4-ijms-20-00317}
----------------

The HANK1 cell line was established in 1998 by Kagami and co-workers \[[@B31-ijms-20-00317]\]. This cell line was derived from a 46-year-old woman with CD56^+^ NK/T-cell lymphoma. HANK1 cells are large polymorphic cells with irregular nuclei and azurophilic granules in the cytoplasm. Immunophenotypic analysis showed that HANK1 cells were positive for CD2, CD3ε, CD56, and CD25. Moreover, HANK1 cells exhibit IL-2 dependence during in vitro culture and retain the biological characteristics of the original tumor cells, allowing them to be used as a model of abnormal nasal-type NK/T-cell lymphoma \[[@B31-ijms-20-00317]\].

3.5. NK-YS Cells {#sec3dot5-ijms-20-00317}
----------------

The NK-YS cell line was established by Tsuchiyama and co-workers in 1996 \[[@B32-ijms-20-00317]\]. This cell line was derived from a 19-year-old woman with leukemic-state nasal angiocentric NK cell lymphoma with systemic skin infiltration. Immunophenotypic analysis showed that NK-YS cells retain the characteristics of prototypic NK lymphoma cells and positively express CD2, CD5, CD7, and CD56, but are negative for CD3, CD16, and CD57.

3.6. KHYG-1 Cells {#sec3dot6-ijms-20-00317}
-----------------

The KHYG-1 cell line was established by Yagita and co-workers in 1997 and was derived from a 45-year-old woman with aggressive NK cell leukemia \[[@B33-ijms-20-00317]\]. KHYG-1 cells have the morphological characteristics of LGLs, i.e., large nuclei, rough chromosomes, obvious nucleoli, abundant cytoplasm, basophilic features, and azurophilic granules. Additionally, these cells rely on IL-2 during in vitro culture. The immunophenotype of KHYG-1 cells is as follows: positive for CD2, CD3ε, CD7, CD8αα, CD33, CD56, CD122, and CD132, and negative for CD1, CD3, CD16, CD25, CD34, and CD57. Suck and co-workers \[[@B34-ijms-20-00317]\] found that the KHYG-1 cell line is more cytotoxic to K562 cells and leukemia cells lines, such as EM2, EM3, and HL60. Additionally, KHYG-1 cells are most likely to regulate cell lysis with perforin by granzyme M (instead of granzymes A and B). Researchers have predicted that KHYG-1 may induce apoptosis in tumor cells through a novel granzyme/perforin pathway.

3.7. SNK-6 and SNT-8 Cells {#sec3dot7-ijms-20-00317}
--------------------------

SNK-6 and SNT-8 cells are nasal NK/T-cell lymphoma cells established in 2001 by Nagata and co-workers in Japan \[[@B35-ijms-20-00317]\]. SNK-6 cells were derived from a 62-year-old Japanese man, and SNT-8 cells were derived from a 48-year-old Japanese woman. These two cell lines were established using a single-cell suspension culture method. Tumor cells from male patients were cultured for 20 months and named SNK-6, and tumor cells from female patients were cultured for 17 months and named SNT-8. Both cell lines rely on IL-2 for growth. Immunophenotypic analysis showed that SNK-6 cells are positive for CD56 and negative for CD3, CD4, CD8, CD19, and TCR (TCRα/β and TCR γ/δ), whereas SNT-8 cells are positive for CD3, CD56, and TCRγ/δ, and negative for CD4, CD8, CD19, and TCRα/β. These two cell lines have been shown to have important applications in studies of cell necrosis caused by nasal T/NK cell lymphoma.

3.8. IMC-1 Cells {#sec3dot8-ijms-20-00317}
----------------

The IMC-1 cell line was established in 2004 by Chen and colleagues \[[@B36-ijms-20-00317]\]. These cells are an IL-2-dependent leukemia cell line obtained from an adult patient with invasive NK cell leukemia. IMC-1 cells express CD56, CD2, CD11a, CD38, and HLA-DR cell surface antigens and lyse target cells in a non-MHC-restricted and antibody-independent manner.

3.9. NK-92 Cells {#sec3dot9-ijms-20-00317}
----------------

The NK-92 cell line was isolated and successfully established by Klingemann's group in 1992 from a 50-year-old man with malignant non-Hodgkin's lymphoma \[[@B37-ijms-20-00317]\]. NK-92 cells express CD2 and CD56 and are negative for CD3, CD4, CD8, and CD16. The growth of NK-92 cells is dependent on the presence of recombinant IL-2; once IL-2 is withdrawn, the cells will die within 72 h. NK-92 cells tend to grow in an aggregated pattern and easily die when dispersed \[[@B24-ijms-20-00317],[@B37-ijms-20-00317]\]. Similar to NK cells, NK-92 cells can kill tumor cells without prior sensitization. Additionally, NK-92 cells lack the CD16 receptor and therefore cannot mediate ADCC. However, these cells still exhibit a high degree of cytotoxic activity toward a variety of cancers cells \[[@B38-ijms-20-00317],[@B39-ijms-20-00317],[@B40-ijms-20-00317]\]. NK-92MI and NK-92CI cells are derived from NK-92 cells and have biological characteristics similar to those of NK-92 cells, but do not rely on IL-2 \[[@B38-ijms-20-00317]\].

4. Progress in the Application of NK-92 Cells {#sec4-ijms-20-00317}
=============================================

Among the several NK cell lines currently established, NK-92 cells lack almost all inhibitory killing receptors and express a series of activating receptors \[[@B42-ijms-20-00317]\]. Additionally, NK-92 cells are abundant in perforin and granzyme, suggesting a broad spectrum of cytotoxic effects. Accordingly, these cells have become a critical NK cell line for preclinical research and are the only NK cell line approved by the US Food and Drug Administration (FDA) for phase I and II clinical studies \[[@B43-ijms-20-00317],[@B44-ijms-20-00317],[@B45-ijms-20-00317],[@B46-ijms-20-00317],[@B47-ijms-20-00317]\].

After the establishment of NK-92 cells, many studies were carried out to demonstrate the potential applications of NK-92 cells in the treatment of tumors. Yan and co-workers \[[@B43-ijms-20-00317],[@B44-ijms-20-00317],[@B45-ijms-20-00317],[@B46-ijms-20-00317],[@B47-ijms-20-00317],[@B48-ijms-20-00317]\] studied the cell-killing effects of NK-92 cells on primary tumor cells derived from various leukemia patients using chromium 51 release tests. The results showed that NK-92 cells were cytotoxic to leukemia cells both in vitro and in vivo. Swift and co-workers studied the cytotoxicity of NK-92 cells to bulk and clonogenic multiple myeloma and evaluated the effects of NK-92 cell treatment in a xenograft mouse model. The results demonstrated that NK-92 cells could effectively kill clonogenic and bulk multiple myeloma cells and could significantly reduce tumor burden in vivo \[[@B49-ijms-20-00317]\].

The growth of NK-92 cells is dependent on the presence of IL-2; however, systemic administration of IL-2 can result in unexpected side effects, such as high toxicity and nonlocalized administration \[[@B50-ijms-20-00317]\]. To make NK-92 cells more suitable for clinical applications, Konstantinidis and co-workers used gene editing to express IL-2 in the endoplasmic reticulum of NK-92 cells; the engineered NK-92 cells could grow normally independent of IL-2 and exhibited the same function and cytotoxicity as NK-92 cells \[[@B50-ijms-20-00317]\].

In combination with current good manufacturing practice (cGMP)-compliant expansion methodologies \[[@B51-ijms-20-00317]\], NK-92 cells are approved for analysis in clinical trials to determine their utility in the treatment of some types of malignant tumors \[[@B47-ijms-20-00317],[@B52-ijms-20-00317]\]. For example, Tam and co-workers \[[@B51-ijms-20-00317]\] demonstrated that when NK-92 cells were irradiated with 500 cGy gamma rays, the proliferation of NK-92 cells was prevented, and their high killing activity was maintained. Moreover, even when the irradiation dose was increased to 1000 cGy, the cytotoxic effects of NK-92 cells were maintained within 48 h. Additionally, Tonn and co-workers \[[@B47-ijms-20-00317]\] conducted a comprehensive study of the possible limitations of NK-92 cells in clinical applications and determined the optimal culture conditions and operating procedures for large-scale expansion under GMP conditions. Subsequently, a phase Ⅰ trial was performed in seven patients with advanced cancer; the NK-92 cells were infused twice per patient with an interval of 48 h, and individual patients developed low-heat, back pain, and other uncomfortable reactions after treatment. Generally, it was found to be safe to infuse 5 × 10^9^/m^2^ of NK-92 cells per patient. Further experiments are needed to determine the efficacy of NK-92 cells in advanced cancer \[[@B47-ijms-20-00317]\].

5. Structure of CARs and Their Applications in NK-92 Cells {#sec5-ijms-20-00317}
==========================================================

In recent studies, major breakthroughs in the use of CAR-T cells for relapsed and refractory B cell malignancies targeting CD19 have been made \[[@B53-ijms-20-00317],[@B54-ijms-20-00317],[@B55-ijms-20-00317],[@B56-ijms-20-00317],[@B57-ijms-20-00317],[@B58-ijms-20-00317],[@B59-ijms-20-00317],[@B60-ijms-20-00317],[@B61-ijms-20-00317],[@B62-ijms-20-00317]\], and two CD19 CAR-T cell products have been approved by the US FDA \[[@B63-ijms-20-00317],[@B64-ijms-20-00317]\].

However, there are many limitations to the use of CAR-T cells, including off-target effects and cytokine storms. Therapy with CAR-T cells has not yet been successful in patients with solid tumors, and the production of autologous cells also has many limitations in the clinical setting \[[@B65-ijms-20-00317]\]. The production of CAR-T cells requires a certain time period, which makes it challenging to prepare a sufficient number of CAR-T cells within a short time for patients whose disease progresses faster. It is also difficult to collect a sufficient number of healthy T cells from the patient. "Off-the-shelf" allogeneic T cells can overcome these difficulties, but may cause severe graft-versus-host disease (GVHD) \[[@B66-ijms-20-00317]\].

CAR-NK-92 cells are highly cytotoxic and can be harvested as phenotypically homogeneous cells, with production of large numbers of cells within a short period. Additionally, compared with CAR-T cells, CAR-NK-92 cells cannot proliferate after irradiation; thus, the survival time in vivo is shorter, avoiding some off-target effects \[[@B67-ijms-20-00317]\]. Even if the targeted antigen on the tumor is rapidly lost, the CAR-NK-92 cells can still be activated by their activating receptors, conferring CAR-NK-92 cells with significant advantages.

5.1. Structure of CARs {#sec5dot1-ijms-20-00317}
----------------------

The traditional CAR vector structure consists of three parts ([Figure 3](#ijms-20-00317-f003){ref-type="fig"}), including an extracellular antigen recognition region, a transmembrane region, and intracellular signal domain, which determine the specificity and functionality of the CAR modification. Current CAR technology is in the fourth generation of development \[[@B68-ijms-20-00317]\]. The first generation of CARs consisted of a single-chain variable fragment (scFv) that recognizes tumor surface antigens, and an immunoreceptor tyrosine-based activation motif (ITAM, usually CD3ζ) \[[@B69-ijms-20-00317]\]. However, the first generation of CARs only caused T cells to proliferate for a short period and did not provide long-term T-cell expansion signals to maintain antitumor effects.

According to the dual-signal model of T-cell activation, the second and third generations of CARs introduced CD28, CD134 (OX40), CD137 (4-1BB) \[[@B70-ijms-20-00317]\], and other costimulatory molecules. The aim was to enhance the antitumor cytotoxicity and proliferative capacity of T cells in vivo.

To more completely remove tumor cells, Chmielewski and co-workers \[[@B71-ijms-20-00317],[@B72-ijms-20-00317]\] designed the "fourth generation" CAR structure. The fourth generation of CARs contains two costimulatory molecules (CD28, CD134, or CD137) and induces the secretion of IL-12 from the cell. In the treatment of solid cancer, fourth-generation CAR-T cells release IL-2 and activate innate immune cells to eliminate antigen-negative cancer cells, thereby increasing the antitumor effect of these cells in vivo by several fold.

### CARs of NK Cells

Similar to CAR-T cells, the goal of CAR-NK cells is to establish a new activation pathway to enhance the antitumor effects of the cells and to improve tumor cell targeting. CAR-NK have the basic framework of CAR-T ([Figure 3](#ijms-20-00317-f003){ref-type="fig"}), including an extracellular antigen recognition region, a transmembrane region, and an intracellular signal domain.

CD3ζ is a classical intracellular signal segment of the CAR structure \[[@B73-ijms-20-00317]\] and plays an important role in NK cells \[[@B74-ijms-20-00317]\]. CAR-NK generally uses CD3ζ as the first signal motif (first-generation CAR) and then a costimulatory molecular motif (second-generation CAR), such as CD28 or CD137 (4-1BB) \[[@B75-ijms-20-00317]\], to form an intracellular signal region.

NKG2D is a crucial activating receptor expressed on most CD8^+^ T cells and NK cells and is a relatively unique activating receptor in NK cells. The NKG2D receptor binds to DAP10 or DAP12 transfer proteins to provide different activation signals \[[@B76-ijms-20-00317]\]. Both signals can activate the cytotoxicity of NK cells, but only the activation signal transmitted by DAP12 can promote the production of cytokines by NK cells \[[@B77-ijms-20-00317]\]. In one study \[[@B78-ijms-20-00317]\], researchers linked DAP10 and CD3ζ to the NK cell activation receptor NKG2D. In an osteosarcoma mouse model, the cytotoxic potential of NK cells against a wide spectrum of tumor subtypes could be markedly enhanced by expression of CAR-NKG2D-DAP10-CD3ζ receptor.

CD244, also known as the NK cell receptor 2B4, is a signal transduction lymphocyte-activating molecule-related receptor expressed in all NK cells \[[@B79-ijms-20-00317]\]. This protein is an important regulator of NK cell activation and was shown to have robust costimulatory roles in a study in which NK cells were used as effector cells to target CD19 or GD2 \[[@B80-ijms-20-00317]\].

5.2. Preclinical Studies of CAR-NK-92 Cells {#sec5dot2-ijms-20-00317}
-------------------------------------------

NK-92 cells are an ideal CAR carrier with natural antitumor properties and are easy to cultivate and modify in vitro. The first generation of CAR has been widely applied in CAR-NK-92 cells ([Table 2](#ijms-20-00317-t002){ref-type="table"}) \[[@B16-ijms-20-00317]\].

Uherek and co-workers \[[@B81-ijms-20-00317]\] reported the expression of an antigen recognition receptor on the surface of NK-92 cells by gene editing. This receptor recognizes the tumor-associated antigen ErbB2, which is overexpressed in various epithelial tumors. Moreover, they used a first-generation technique similar to CAR-T cells. The entire CAR structure included the extracellular region ErbB2-specific scFv (FRP5) antibody fragment, a CD8 hinge region, a transmembrane region, and an intracellular CD3ζ chain. In vitro experiments indicated that compared with the parental cells, the genetically modified NK-92-scFv (FRP5)-CD3ζ cells were able to specifically recognize and effectively kill ErbB2-expressing tumor cells from different sources. Subsequently, CAR-NK-92, the first-generation CAR structure of different targets, showed good effects against hematomas and solid tumors. This structure also included CD19 and CD20 for B cell leukemia and lymphoma \[[@B82-ijms-20-00317],[@B83-ijms-20-00317],[@B84-ijms-20-00317],[@B85-ijms-20-00317]\], CD138 for myeloma \[[@B86-ijms-20-00317]\], human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor for brain metastasis \[[@B87-ijms-20-00317],[@B88-ijms-20-00317],[@B89-ijms-20-00317]\], HER2 and EGFR for breast cancer \[[@B81-ijms-20-00317],[@B90-ijms-20-00317],[@B91-ijms-20-00317],[@B92-ijms-20-00317],[@B93-ijms-20-00317],[@B94-ijms-20-00317]\], and GD2 for neuroblastoma \[[@B95-ijms-20-00317],[@B96-ijms-20-00317]\]. Additionally, NK-92 cells do not express CD16 and therefore do not mediate the effects of ADCC. In recent years, methods for expressing CD16 have been established, and expression of CD16 in NK-92 cells can effectively enhance the antitumor effects of the cells \[[@B97-ijms-20-00317]\]. Boissel and co-workers demonstrated that CAR-NK-92 cells have the ability to clear chronic lymphocytic leukemia cells to a greater extent than NK-92 cells expressing CD16 \[[@B85-ijms-20-00317]\].

The efficacy and safety of CAR-NK-92 cells based on second- and third-generation CARs ([Table 3](#ijms-20-00317-t003){ref-type="table"}) were also confirmed in preclinical trials.

In one study, Oelsner and co-workers \[[@B83-ijms-20-00317]\] compared the cytotoxic effects of CAR-CD19-CD3ζ-NK-92, CAR-CD19-CD28-CD3ζ-NK-92, and CAR-CD19-CD137-CD3ζ-NK-92 on established B-cell leukemia and lymphoma cells. The results showed that all three CD19-specific CAR-NK-92 cell lines were effective at killing B cell malignancies. However, CAR-CD19-CD137-CD3ζ-NK-92 cells were less effective than CAR-CD19-CD3ζ-NK-92 and CAR-CD19-CD28-CD3ζ-NK-92 cells at cell killing and cytokine production, indicating the differential effects of the costimulatory CD28 and CD137 domains. In a recent study \[[@B98-ijms-20-00317]\], researchers at the University of California, San Diego evaluated the effects of different CAR constructs on NK cell-mediated killing. They designed nine CAR constructs that target mesothelin. The killing experiments in vitro revealed that a CAR containing the transmembrane domain of NKG2D, the 2B4 costimulatory domain, and the CD3ζ signaling domain of CAR could mediate strong antigen-specific NK cell signaling. Subsequently, the effects of CAR-NK and CAR-T cells were compared in a mouse model. The results showed that CAR-NK cells had in vivo activities similar to those of as CAR-T cells, but with less toxicity. This research indicated that CAR-NK cell therapy may be safer than CAR-T cell therapy.

5.3. Ongoing Clinical Trials {#sec5dot3-ijms-20-00317}
----------------------------

Clinical trials examining CAR-NK-92 cells for the treatment of tumors are being carried out ([Table 4](#ijms-20-00317-t004){ref-type="table"}). However, compared with CAR-T cells that have been applied in clinical studies, fewer clinical studies have been performed for CAR-NK-92 cells \[[@B8-ijms-20-00317],[@B99-ijms-20-00317]\], and little clinical data have been published.

In a recent clinical trial (NCT02944162), Tang and co-workers \[[@B100-ijms-20-00317]\] revealed the efficacy and safety of CAR-NK-92 cells in the treatment of relapsed and refractory acute myeloid leukemia. In this study, a total of three patients received therapy with CD33-CAR NK-92 cells. The first patient was a 14-year-old girl and the second patient was a 24-year-old male, who both received doses of 3 × 10^8^, 6 × 10^8^, and 1 × 10^9^ cells on days 1, 3, and 5, respectively. Another patient was a 49-year-old woman who received doses of 1 × 10^9^, 3 × 10^9^, and 5 × 10^9^ cells on days 1, 4 and 7, respectively. All patients had mild symptoms after treatment, including fever and cytokine release syndrome, but returned to normal the next day. This is the first phase Ⅰ clinical trial of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Although the treatment effect was not significant, the findings of this clinical study showed that CAR-NK-92 cells can be safely used.

5.4. Advantages of CAR-NK-92 Cells {#sec5dot4-ijms-20-00317}
----------------------------------

CAR-NK cells are potential competitors for CAR-T cells. CAR-NK-92 cells do not cause GVHD \[[@B111-ijms-20-00317]\] and have greater cytotoxicity than ADCC \[[@B85-ijms-20-00317]\]. Indeed, CAR-NK-92 cells have many advantages, as follows: (1) CAR-NK-92 cells can target tumor cells and directly activate NK-92 cells to kill target cells; (2) even if the targeted antigen on the tumor is rapidly lost, the CAR-NK-92 cells can still be activated by their activating receptors \[[@B8-ijms-20-00317]\]; (3) the inhibitory receptors are expressed at low levels on the surface \[[@B37-ijms-20-00317]\] and deletion of inhibitory receptors makes NK-92 cells more resistant to solid tumors than other immune cells; and (4) NK-92 cells are immortalized cell lines with a uniform phenotype, allowing them to be cultured in vitro for a long time to proliferate. CAR-NK-92 cells also have this advantage, which can compensate for the decline in immune cell viability in patients with advanced cancer. Depending on the type of tumor, corresponding CAR-NK-92 cells can be directly expanded for treatment, thereby shortening the treatment cycle and reducing the cost of treatment \[[@B112-ijms-20-00317]\].

5.5. Challenges and Coping Strategies {#sec5dot5-ijms-20-00317}
-------------------------------------

Although CAR-NK-92 cells have good antitumor effects, there are still some problems that need to be solved to make them more suitable for clinical treatment.

### 5.5.1. Tumor-Producing and Potential Epstein-Barr (EB) Virus Susceptibility {#sec5dot5dot1-ijms-20-00317}

NK-92 cells are derived from patients with malignant non-Hodgkin's lymphoma; they may cause secondary tumorigenesis and potential EB virus susceptibility after injection. Therefore, for safety reasons, NK-92 cells need to be lethally irradiated before clinical application \[[@B16-ijms-20-00317]\].

### 5.5.2. NK-92 Cells Have A Short Life Cycle after Irradiation {#sec5dot5dot2-ijms-20-00317}

After irradiation, CAR-NK-92 cells survive in vivo for a short period. This method reduces the side effects of CAR-NK-92 cells on the body, while also reducing the antitumor effects; thus, therapy may require multiple injections.

### 5.5.3. Defects in the Transfected Vector {#sec5dot5dot3-ijms-20-00317}

Genetic modification of cells is a critical step to realizing CAR expression. Virus transduction is the most common method used for genetic modification. These viral vectors include retroviral vectors, lentiviral vectors, and adenoviral vectors, among which retroviral vectors and lentiviral vectors are most widely used. Viral vectors are capable of ensuring stable expression of the transgene. However, the viral vector itself may be related to high production costs, a long reproduction cycle, and complexity. Additionally, viral vectors alone cannot accurately insert genes into the desired location, posing potential risks; for example, they may affect the expression of normal genes or cause the inserted genes to be abnormally regulated. Accordingly, it is essential to develop non-viral vectors. The CRISPR-Cas9 system can be combined with electroporation techniques to precisely insert genes into the genome and achieve stable expression. Roth and co-workers \[[@B113-ijms-20-00317]\] successfully demonstrated that the system can successfully edit the genome at low cost and complete T-cell modification in just a few weeks.

### 5.5.4. Off-Target Effects {#sec5dot5dot4-ijms-20-00317}

CAR-NK-92 cells are target dependent and mainly kill cells with high expression of specific antigens. However, once the antigens are also expressed in normal tissues and cells, off-target toxicity can occur. Currently, there are no specific clinical data to assess the severity of the off-target toxicity of CAR-NK-92 cells. Accordingly, it is necessary to consider dose control and other factors (e.g., introducing suicide genes) in order to reduce the risk of toxicity \[[@B114-ijms-20-00317]\].

6. Conclusions and Perspectives {#sec6-ijms-20-00317}
===============================

The antitumor ability of NK cells confers them with broad potential applications in cell therapy. NK cells modified by CAR have also been shown to be promising as effector cells. However, the exploration of CAR-NK cells is still at a preliminary stage. It is necessary to examine which types of CAR structures are most effective for activating NK cells and which intracellular signal domains can maintain the killing ability of NK cells for a long time. Although currently used viral vectors can be stably integrated into the genome, there is a risk of random insertion. Thus, development of new non-viral transfection methods is necessary. NK-92 cells, an immortalized cell line, can be quickly and easily obtained in the clinical setting. Additionally, the cells must be subjected to lethal radiation before use in order to avoid the risk of secondary tumorigenicity. Controllable NK-92 cells, such as those expressing a combination of suicide genes, should be further explored. With advancements in CAR-NK technology and the accumulation of clinical experience, combination of CAR-NK cells with other anticancer therapies may also show efficacy. Although CAR-NK cells induce a low incidence of cytokine storms and induce few side effects compared with CAR-T cells, further studies are needed to fully assess the safety of these cells. As preclinical trials and clinical studies proceed, NK cells are expected to play important roles in the treatment of cancer.
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Antibody dependent cell mediated cytotoxicity
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HER2

Human epidermal growth factor receptor 2

IL-2

Interleukin-2

ITAMs

Immunoreceptor tyrosine-based activation motif

KIRs

Killer immunoglobulin-like receptor
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Large granular lymphocytes

MHC

Major histocompatibility complex

NK

Natural killer

PB

Peripheral blood

scFv

Single-chain variable fragment

TCR

T-cell receptor

TNF

Tumor necrosis factor

![Major receptors expressed on the surface of natural killer (NK) cells. NKp46, natural killer cell p46-related protein; NKp44, natural killer cell p44-related protein; NKp30, natural killer cell p30-related protein; CD, Cluster of differentiation; NKG2, also known as CD159; KIR, killer-cell immunoglobulin-like receptor; TIGIT, T cell immunoreceptor with Ig and ITIM domains; LAG3, lymphocyte activation gene 3 protein; TIM3, T cell immunoglobulin mucin receptor 3; PD1, programmed cell death protein 1; KLRG1, killer cell lectin-like receptor subfamily G member 1; IL-2R, interleukin-2 receptor; TGFβR, transforming growth factor beta receptors.](ijms-20-00317-g001){#ijms-20-00317-f001}

![Mechanisms of cytotoxicity by natural killer (NK) cells.](ijms-20-00317-g002){#ijms-20-00317-f002}

![Generations of CAR design. The traditional CAR vector structure consists of three parts: an extracellular antigen recognition region, a transmembrane region, and an intracellular signal domain. The extracellular domain of CAR includes an scFv region (H \[heavy\] and L \[light\] chain) that is spliced by a linker. A hinge ensures flexibility and connects to the transmembrane domain. The intracellular domain includes a CD3ζ signaling domain and costimulatory domains, such as CD28, CD134, CD137, and 2B4.](ijms-20-00317-g003){#ijms-20-00317-f003}
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###### 

Currently known NK cell lines.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell Line   Year   Disease Diagnosis                                                                      Patient              Doubling Time   Viral Status   Cytokine                  Primary Reference
  ----------- ------ -------------------------------------------------------------------------------------- -------------------- --------------- -------------- ------------------------- -----------------------------------------------
  NK3.3       1982   NR                                                                                     NR                   NR              EBV^−^         IL-2-dependent            \[[@B23-ijms-20-00317]\]

  YT          1983   Acute lymphoblastic lymphoma (with thymoma)                                            15-year-old male     40--50 h        EBV^+^         Independent of IL-2       \[[@B27-ijms-20-00317]\]

  NKL         1996   NK-LGLL                                                                                63-year-old male     24--48 h        NR             IL-2-dependent            \[[@B30-ijms-20-00317],[@B41-ijms-20-00317]\]

  HANK1       1998   Nasal-like NK/T-cell lymphoma                                                          46-year-old female   3 day           EBV^+^         IL-2-dependent            \[[@B31-ijms-20-00317]\]

  NK-YS       1996   NK cell lymphoma, Nasal angiocentric, Leukemic state with systemic skin infiltration   19-year-old female   48 h            EBV^+^         IL-2-dependent            \[[@B32-ijms-20-00317]\]

  KHYG-1      1997   Aggressive NK leukemia                                                                 45-year-old female   24--48 h        EBV^−^         IL-2-dependent            \[[@B33-ijms-20-00317]\]

  SNK-6       1998   Nasal NK/T-cell lymphoma                                                               62-year-old male     NR              EBV^+^         IL-2-dependent            \[[@B35-ijms-20-00317]\]

  SNT-8       1998   Nasal NK/T-cell lymphoma                                                               48-year-old female   NR              EBV^+^         IL-2-dependent            \[[@B35-ijms-20-00317]\]

  IMC-1       2004   Aggressive NK cell leukemia                                                            42-year-old male     24--36 h        EBV^−^         IL-2-dependent            \[[@B36-ijms-20-00317]\]

  NK-92       1992   LGL-NHL                                                                                50-year-old male     24 h            EBV^−^         IL-2-dependent;\          \[[@B37-ijms-20-00317]\]
                                                                                                                                                                Growth stimulation:IL-7   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR, not reported; EBV, Epstein-Barr virus; NK, natural killer cell; LGL: large granular lymphocyte; LGLL: large granular lymphocyte leukemia; NHL: non-Hodgkin's lymphoma.
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###### 

Preclinical studies with the first generation of CAR-NK-92 cells.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer Type                                Antigen Targeted   Hinge   TM       Intracellular Signal Domain   Genetic Modification Method   Effector Cell   Year   References
  ------------------------------------------ ------------------ ------- -------- ----------------------------- ----------------------------- --------------- ------ ---------------------------
  Multiple myeloma                           CD138              CD8     CD3ζ     CD3ζ                          lentiviral vector             NK-92MI         2014   \[[@B86-ijms-20-00317]\]

  B-cell malignancies                        CD19               CD8     NR       CD3ζ                          Retrovirus                    NK-92           2016   \[[@B82-ijms-20-00317]\]

  B-cell malignancies                        CD19               CD8     CD28     CD3ζ                          Lentiviral                    NK-92           2017   \[[@B83-ijms-20-00317]\]

  CLL                                        CD19               CD8     CD3ζ     CD3ζ                          Electroporation               NK-92           2009   \[[@B84-ijms-20-00317]\]

  ALL\                                       CD19\              NR      NR       CD3ζ                          Lentivirus                    NK-92           2014   \[[@B85-ijms-20-00317]\]
  CLL                                        CD20                                                                                                                   

  B-cell malignancies                        CD20               CD8     CD3ζ     CD3ζ                          Retroviral                    NK-92           2008   \[[@B101-ijms-20-00317]\]

  Prostate cancer                            EpCAM              CD8     CD3ζ     CD3ζ                          Retrovirus                    NK-92           2009   \[[@B102-ijms-20-00317]\]

  Prostate cancer                            EpCAM              CD8     CD3ζ     CD3ζ                          Retrovirus                    NK-92           2011   \[[@B103-ijms-20-00317]\]

  Neuroblastoma                              GD2                CD8     CD3ζ     CD3ζ                          Retrovirus                    NK-92           2012   \[[@B96-ijms-20-00317]\]

  Neuroblastoma                              GD2                CD8     CD3ζ     CD3ζ                          Retrovirus                    NK-92           2015   \[[@B95-ijms-20-00317]\]

  Melanoma                                   GPA7               NR      HLA-A2   CD3ζ                          Electroporation               NK-92MI         2013   \[[@B104-ijms-20-00317]\]

  Brain metastasis                           HER2               CD8α    CD3ζ     CD3ζ                          Retrovirus                    NK-92           2016   \[[@B88-ijms-20-00317]\]

  Brain metastasis                           HER2               CD8     CD3ζ     CD3ζ                          Retrovirus                    NK-92           2013   \[[@B89-ijms-20-00317]\]

  Breast cancer                              HER2               CD8     CD3ζ     CD3ζ                          Retrovirus                    NK-92           2005   \[[@B91-ijms-20-00317]\]

  Breast cancer                              HER2               CD8     CD3ζ     CD3ζ                          Retrovirus                    NK-92           2008   \[[@B92-ijms-20-00317]\]

  Breast/ovarian cancer                      HER2               CD8     CD3ζ     CD3ζ                          Retrovirus                    NK-92           2002   \[[@B81-ijms-20-00317]\]

  Breast cancer, Ovarian cancer, Melanoma\   HER2               CD8     CD3ζ     CD3ζ                          Lentiviral                    NK-92           2015   \[[@B93-ijms-20-00317]\]
  Renal cell carcinoma                                                                                                                                              

  Ovarian cancer\                            Mesothelin         CD8     NKG2D    CD3ζ                          Transposon plasmids           NK-92           2018   \[[@B98-ijms-20-00317]\]
  Mesothelin-expressing tumors                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ijms-20-00317-t003_Table 3

###### 

Preclinical studies with the second and third generations of CAR-NK-92 cells.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cancer Type                                   Antigen Targeted   Hinge   TM      Intracellular Signal Domain   Genetic Modification Method   Effector Cell   Year   References
  --------------------------------------------- ------------------ ------- ------- ----------------------------- ----------------------------- --------------- ------ ---------------------------
  B-cell malignancies                           CD19               CD8     CD28    CD28-CD3ζ\                    Lentiviral                    NK-92           2017   \[[@B83-ijms-20-00317]\]
                                                                                   CD137-CD3ζ                                                                         

  Multiple myeloma                              CS1                NR      NR      CD28-CD3ζ                     Lentivirus                    NK-92           2014   \[[@B105-ijms-20-00317]\]

  EBV^+^ cells                                  EBNA3C             NR      NR      CD137-CD3ζ                    Retrovirus                    NK-92MI         2012   \[[@B75-ijms-20-00317]\]

  Glioblastoma                                  EGFR\              NR      CD28    CD28-CD3ζ                     Lentivirus                    NK-92 and NKL   2015   \[[@B106-ijms-20-00317]\]
                                                EGFRvIII                                                                                                              

  Brain metastasis                              EGFR               NR      NR      CD28-CD3ζ                     Lentivirus                    NK-92           2016   \[[@B87-ijms-20-00317]\]

  Glioblastoma                                  EGFR\              CD8     CD28    CD28-CD3ζ                     Lentivirus                    NK-92           2015   \[[@B107-ijms-20-00317]\]
                                                EGFRvIII                                                                                                              

  Breast cancer                                 EpCAM              CD8     CD28    CD28-CD3ζ                     Lentivirus                    NK-92           2012   \[[@B90-ijms-20-00317]\]

  Breast cancer\                                HER2               CD8     CD28\   CD28-CD3ζ\                    Lentiviral                    NK-92           2015   \[[@B93-ijms-20-00317]\]
  Renal cell carcinoma\                                                    CD137   CD137-CD3ζ                                                                         
  Ovarian carcinoma Melanoma                                                                                                                                          

  Glioblastoma                                  HER2               CD8     CD28    CD28-CD3ζ                     Lentiviral                    NK-92           2016   \[[@B108-ijms-20-00317]\]

  Breast cancer                                 HER2               CD8     CD28    CD28-CD3ζ                     Electroporation               NK-92           2015   \[[@B94-ijms-20-00317]\]

  Ovarian cancer\                               Mesothelin         CD8     CD16    2B4-CD3ζ                      Transposon plasmids           NK-92           2018   \[[@B98-ijms-20-00317]\]
  Mesothelin-expressing tumors                                                                                                                                        

  Ovarian cancer mesothelin-expressing tumors   Mesothelin         CD8     NKp44   DAP10-CD3ζ\                   Transposon plasmids           NK-92           2018   \[[@B98-ijms-20-00317]\]
                                                                                   2B4-CD3ζ                                                                           

  Ovarian cancer\                               Mesothelin         CD8     NKG2D   2B4-CD3ζ\                     Transposon plasmids           NK-92           2018   \[[@B98-ijms-20-00317]\]
  Mesothelin-expressing tumors                                                     CD137-CD3ζ                                                                         

  Ovarian cancer\                               Mesothelin         CD8     CD28    CD28-CD137-CD3ζ               Transposon plasmids           NK-92           2018   \[[@B98-ijms-20-00317]\]
  Mesothelin-expressing tumors                                                                                                                                        

  Ovarian cancer\                               Mesothelin         CD8     NKG2D   2B4-DAP12-CD3ζ\               Transposon plasmids           NK-92           2018   \[[@B98-ijms-20-00317]\]
  Mesothelin-expressing tumors                                                     2B4-DAP10-CD3ζ\                                                                    
                                                                                   CD137-2B4-CD3ζ                                                                     

  Aggressive T cell malignancies                CD3                CD8     CD8     CD28-CD137-CD3ζ               Lentivirus                    NK-92           2016   \[[@B109-ijms-20-00317]\]

  Aggressive T-cell malignancies                CD5                CD8     CD8     CD28-CD137-CD3ζ               Lentivirus                    NK-92           2017   \[[@B110-ijms-20-00317]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR, not reported; ALL, acute lymphoblastic leukemia; B-ALL, B-cell acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; TM, transmembrane domain; TAMs, tumor-associated macrophages.

ijms-20-00317-t004_Table 4

###### 

Clinical trials with CAR-NK-92 cells.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NCT Number    NK Cell Source   Target Antigen   Disease                                                                                                                                                                                                                                                                                                                                          Phase      Estimated Enrollment   Age                                               Location   References
  ------------- ---------------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------- ---------------------- ------------------------------------------------- ---------- ---------------------------
  NCT02742727   NK-92            CD7              Acute Myeloid Leukemia;Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; T-cell Prolymphocytic Leukemia; T-cell Large Granular Lymphocytic Leukemia; Peripheral T-cell Lymphoma, NOS; Angioimmunoblastic T-cell Lymphoma Extranodal NK/T-cell Lymphoma, Nasal Type; Enteropathy-type Intestinal T-cell Lymphoma; Hepatosplenic T-cell Lymphoma   Phase 1\   10 participants        18 Years and older (Adult, Older Adult)           China      NR
                                                                                                                                                                                                                                                                                                                                                                                                   Phase 2                                                                                        

  NCT02892695   NK-92            CD19             Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma; Mantle Cell Lymphoma; B-cell Prolymphocytic Leukemia; Diffuse Large Cell Lymphoma;                                                                                                                                                                                Phase 1\   10 participants        3 Years to 80 Years (Child, Adult, Older Adult)   China      NR
                                                                                                                                                                                                                                                                                                                                                                                                   Phase 2                                                                                        

  NCT02944162   NK-92            CD33             Acute Myelogenous Leukemia; Acute Myeloid Leukemia; Acute Myeloid Leukemia with Maturation; Acute Myeloid Leukemia Without Maturation; ANLL                                                                                                                                                                                                      Phase 1\   10 participants        3 Years to 80 Years (Child, Adult, Older Adult)   China      \[[@B100-ijms-20-00317]\]
                                                                                                                                                                                                                                                                                                                                                                                                   Phase 2                                                                                        

  NCT03383978   NK-92            HER2             Glioblastoma                                                                                                                                                                                                                                                                                                                                     Phase 1    30 participants        18 Years and older (Adult, Older Adult)           Germany    NR

  NCT03656705   NK-92            NR               Non-small Cell Lung Cancer                                                                                                                                                                                                                                                                                                                       Phase 1    5 participants         18 Years to 75 Years (Adult, Older Adult)         China      NR
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR, not reported; Data are from <http://www.clinicaltrials.gov>.
